We provided evidence that the C1858T PTPN22 gene polymorphism [6,18] could be a relevant target for immunomodulation in the treatment of C1858T patients affected by an autoimmune disease, that is, T1D [6,27]. The gene discussed is PTPN22; the disease is autoimmune disease.